Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Multiple Sclerosis
Longest Study of Drug Shows Benefits Continue for Six Years
September 9th, 2000
Results of a six-year study show that sustained use of the drug Copaxone significantly reduces the relapse rate and also delays disability in people with the relapsing-remitting form of multiple sclerosis (MS). The study, published in the August 2000 issue of the journal Multiple Sclerosis, is the longest evaluation so far of a licensed MS therapy. The study is scheduled to continue until mid-2002, when participants will have been evaluated for 10 years. Of the 101 people receiving daily injections of Copaxone during the past six years, 77 have had three or fewer relapses, and 26 have not had any relapses. Study participants also experienced a steady decline...
Source: Pain & Central Nervous System Week (2000-09-09)
|
